Trulicity Cost in Hawaii 2026: Pricing, Insurance, and Savings Options

What Does Trulicity Cost in Hawaii Without Insurance?

The retail cash price for Trulicity in Hawaii sits at $931 per month in 2026, matching Eli Lilly's national list price. This buys a carton of four single-dose pens (one pen per week). Hawaii's geographic isolation does not add a retail markup for branded GLP-1 receptor agonists distributed through major wholesalers, so the shelf price mirrors mainland figures [1].

That $931 figure applies across all four approved dose strengths: 0.75 mg, 1.5 mg, 3.0 mg, and 4.5 mg. Dose escalation does not change the monthly cost at the pharmacy counter, because each carton contains four pens regardless of strength. For patients paying entirely out of pocket, annualized spending reaches $11,172 before any discount programs or coupons.

Compared to other GLP-1 receptor agonists available in Hawaii, Trulicity's list price falls below semaglutide (Ozempic) at roughly $935 per month but above older agents like exenatide extended-release (Bydureon BCise) [2]. The REWIND trial (N=9,901) demonstrated that dulaglutide 1.5 mg reduced major adverse cardiovascular events (MACE) by 12% versus placebo over a median 5.4-year follow-up (HR 0.88, 95% CI 0.79 to 0.99), an outcome that contributed to its cardiovascular indication from the FDA [3]. That cardiovascular benefit is relevant to cost discussions because it may influence payer willingness to cover the drug or approve exceptions.

Does Hawaii Medicaid Cover Trulicity?

Hawaii Medicaid does not cover Trulicity as of 2026. Dulaglutide is absent from the Hawaii Medicaid preferred drug list for type 2 diabetes management. Patients enrolled in Hawaii Medicaid plans (including managed care organizations like AlohaCare, HMSA, Kaiser, and UnitedHealthcare Community Plan) will find that prior authorization requests for Trulicity are typically denied in favor of formulary-preferred alternatives [4].

The preferred GLP-1 receptor agonist on most Hawaii Medicaid formularies is exenatide extended-release, with metformin, sulfonylureas, and SGLT2 inhibitors serving as first-line agents. Patients who have documented failure on or contraindication to preferred agents may submit a medical exception request. Success rates for these exceptions vary by plan.

Hawaii's Medicaid program covers approximately 400,000 residents. For those who need dulaglutide specifically (for example, because the REWIND trial's cardiovascular benefit applies to their clinical profile), the exception process requires the prescriber to document prior therapeutic failures and provide clinical justification [3]. Dr. Vanita Aroda, who served as a lead REWIND investigator, noted that "dulaglutide's cardiovascular benefit was consistent across subgroups, including those with and without established cardiovascular disease" [3]. This statement from the REWIND publication can support exception requests when cardiovascular risk reduction is the clinical rationale.

Insurance Coverage for Trulicity in Hawaii

Commercial insurance is the most reliable pathway to affordable Trulicity in Hawaii. The three largest commercial insurers operating in the state (HMSA, Kaiser Permanente Hawaii, and UnitedHealthcare) each maintain formulary positions for GLP-1 receptor agonists, though tier placement and prior authorization requirements differ.

HMSA, which covers roughly 50% of Hawaii's commercially insured population, lists Trulicity on its specialty or non-preferred brand tier. Prior authorization is required. Kaiser Permanente Hawaii manages its own closed formulary and may prefer semaglutide or other GLP-1 agents over dulaglutide depending on the plan year. UnitedHealthcare commercial plans in Hawaii generally cover Trulicity with step therapy, requiring documented trial of metformin first [5].

Typical commercial copays after prior authorization approval range from $50 to $150 per month on non-preferred brand tiers. Patients on high-deductible health plans face the full $931 until their deductible is met. The American Diabetes Association's Standards of Care (2024) recommend GLP-1 receptor agonists with proven cardiovascular benefit as preferred second-line agents after metformin in patients with established atherosclerotic cardiovascular disease (ASCVD) or high ASCVD risk [6]. This guideline language strengthens prior authorization appeals for Trulicity when the prescriber documents cardiovascular risk.

How the Eli Lilly Savings Card Works in Hawaii

Eli Lilly offers a manufacturer savings card that can reduce Trulicity costs to as little as $25 per monthly fill. The card is accepted at all major chain pharmacies in Hawaii, including CVS (Longs Drugs), Walgreens, Walmart, and Costco locations across Oahu, Maui, Big Island, and Kauai.

Eligibility requires commercial insurance. The card cannot be used by patients enrolled in any federal or state government program, including Medicare Part D, Medicaid, TRICARE, or VA benefits. This restriction is federal law, not an Eli Lilly policy, and applies uniformly across all 50 states [7].

For commercially insured Hawaii residents who qualify, the savings card covers the difference between the patient's copay and $25, up to a maximum annual benefit. The 2026 program cap is typically around $150 per fill in covered savings. Patients should verify the current cap directly on the Eli Lilly Trulicity savings card portal, as terms update annually.

Patients without insurance do not qualify for this card. Uninsured patients should consider the Lilly Cares Patient Assistance Program, which provides Trulicity at no cost to qualifying individuals whose household income falls below 400% of the federal poverty level [7]. Application requires prescriber involvement and income documentation.

Compounded Dulaglutide in Hawaii: Legality and Access

Compounded dulaglutide is available in Hawaii through licensed 503A compounding pharmacies. Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound medications, including GLP-1 receptor agonists, based on valid individual patient prescriptions [8].

Hawaii does not impose additional state-level restrictions on 503A compounding of dulaglutide beyond federal requirements. The compounding pharmacy must hold a valid Hawaii Board of Pharmacy license, use ingredient-grade dulaglutide active pharmaceutical ingredient (API) sourced from an FDA-registered facility, and prepare each prescription for an individual patient based on a prescriber's order.

Cost is the primary motivator. Compounded dulaglutide from 503A pharmacies may cost significantly less than the branded $931 per month price, though exact pricing varies by pharmacy, dose, and volume. However, compounded versions are not FDA-approved products. They do not undergo the same manufacturing controls, stability testing, or bioequivalence evaluation as Eli Lilly's branded Trulicity pens [8].

The Endocrine Society has cautioned that compounded peptides carry risks related to potency variability and sterility that branded products do not [9]. Patients considering compounded dulaglutide should verify that the pharmacy holds current 503A licensure (not 503B outsourcing facility status, which operates under different rules) and should discuss the risk-benefit profile with their prescriber. The FDA has stated that it "cannot assure the safety and effectiveness of compounded drugs" [8].

Telehealth Prescribing of Trulicity in Hawaii

Hawaii permits telehealth prescribing of Trulicity. A licensed prescriber can evaluate a patient via synchronous audio-video visit and issue a prescription for dulaglutide without requiring an in-person examination first. This has been the standard since Hawaii codified its telehealth parity law (Hawaii Revised Statutes §453-1.3 and §431:10A-116.3) [10].

For patients on the neighbor islands (Maui, Kauai, Big Island, Molokai, Lanai), telehealth eliminates the need to travel to Oahu for endocrinology or obesity medicine consultations. Prescriptions issued via telehealth can be filled at any Hawaii-licensed pharmacy, including mail-order pharmacies that ship within the state.

Telehealth platforms that operate in Hawaii must use prescribers licensed by the Hawaii Medical Board. Interstate telehealth through compact agreements also applies, as Hawaii participates in the Interstate Medical Licensure Compact [10]. The AWARD-11 trial (N=1,842) established that dulaglutide at the higher 3.0 mg and 4.5 mg doses produced HbA1c reductions of 1.5% and 1.6% respectively versus 1.3% with the 1.5 mg dose at 36 weeks, data that prescribers can reference when titrating patients seen via telehealth [11].

How to Get the Lowest Price on Trulicity in Hawaii

Five strategies exist for reducing Trulicity costs in Hawaii. Patients should evaluate each based on their insurance status and clinical situation.

1. Eli Lilly Savings Card (commercially insured). Reduces copays to $25 per fill. Apply online through the manufacturer's portal. Not valid with government insurance.

2. Lilly Cares Patient Assistance Program (uninsured or underinsured). Provides Trulicity at no cost. Income must fall below 400% FPL. Requires prescriber signature on the application [7].

3. Pharmacy benefit manager (PBM) negotiation. Patients with employer-sponsored coverage can ask their HR department whether the PBM has negotiated a better net price for Trulicity versus competing GLP-1 agents. Formulary positions shift annually.

4. Compounded dulaglutide via 503A pharmacy. Lower sticker price, but no FDA approval. Appropriate for patients who accept the trade-off and whose prescriber supports this route.

5. Prescription discount cards (GoodRx, RxSaver). Cash-pay discount aggregators may reduce the retail price by 5% to 15% at specific Hawaii pharmacies, but the absolute price remains high (typically $780 to $890 per month after discount). These cards cannot be combined with insurance copays [12].

The Endocrine Society's 2023 clinical practice guideline on pharmacological treatment of obesity recommends GLP-1 receptor agonists as first-line pharmacotherapy alongside lifestyle modification for adults with BMI ≥30 kg/m² or BMI ≥27 kg/m² with weight-related comorbidities [9]. While Trulicity is FDA-approved for type 2 diabetes and not for obesity, the guideline context illustrates the growing demand and payer awareness of this drug class. Dr. Beverly Tchang, an obesity medicine physician at Weill Cornell Medicine, has stated: "Access to GLP-1 receptor agonists remains the primary barrier for patients, not efficacy. The drugs work. The system doesn't always cooperate."

Trulicity Dosing and Clinical Background

Dulaglutide is a GLP-1 receptor agonist administered as a once-weekly subcutaneous injection. The FDA approved it in 2014 for type 2 diabetes management, and it received a supplemental cardiovascular indication in 2020 based on the REWIND trial results [3].

The four available doses are 0.75 mg (starting dose), 1.5 mg, 3.0 mg, and 4.5 mg. The Trulicity prescribing information recommends starting at 0.75 mg once weekly for at least four weeks before escalating to 1.5 mg [1]. Patients requiring additional glycemic control can increase to 3.0 mg after at least four weeks at 1.5 mg, and then to 4.5 mg after at least four weeks at 3.0 mg.

In the REWIND trial, 9,901 participants with type 2 diabetes (mean age 66.2 years, 46.3% female, mean HbA1c 7.2%) received dulaglutide 1.5 mg or placebo. The primary MACE endpoint occurred in 12.0% of the dulaglutide group versus 13.4% of the placebo group (HR 0.88, P=0.026) over a median 5.4-year follow-up [3]. 31% of REWIND participants did not have established cardiovascular disease at enrollment, making it the only GLP-1 RA cardiovascular outcomes trial to enroll a substantial primary prevention population.

Common adverse effects include nausea (affecting 12.4% of patients at the 1.5 mg dose), diarrhea (8.9%), vomiting (6.0%), and abdominal pain (6.5%). These gastrointestinal effects typically diminish after 2 to 4 weeks of continued use [1].

Comparing Trulicity to Other GLP-1 Options Available in Hawaii

Hawaii pharmacies stock all major branded GLP-1 receptor agonists. The monthly list prices in 2026 are approximately: Ozempic (semaglutide) at $935, Trulicity (dulaglutide) at $931, Mounjaro (tirzepatide) at $1,023, and Bydureon BCise (exenatide ER) at $730 [2].

The SUSTAIN-7 trial (N=1,201) directly compared semaglutide 0.5 mg and 1.0 mg to dulaglutide 0.75 mg and 1.5 mg over 40 weeks. Semaglutide 1.0 mg produced a 1.8% HbA1c reduction versus 1.4% with dulaglutide 1.5 mg (P<0.0001), along with greater weight loss (6.5 kg vs. 3.0 kg) [13]. These efficacy differences may influence which agent a prescriber selects, and they also affect insurance formulary preferences.

For Hawaii patients whose primary concern is cost, the decision often comes down to which drug their insurance formulary prefers. A non-preferred brand with a $150 copay is more expensive out-of-pocket than a preferred brand with a $50 copay, regardless of list price differences. Checking the specific formulary before the prescriber writes the prescription saves time and money.